EUCTR2018-001036-21-IT
Active, Not Recruiting
Phase 1
Phase II monocentric study on prostate cancer restaging using PET/MR with innovative radiotracers - PCa Restaging- PET/MR
OSPEDALE SAN RAFFAELE0 sites60 target enrollmentNovember 6, 2018
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Radically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)
- Sponsor
- OSPEDALE SAN RAFFAELE
- Enrollment
- 60
- Status
- Active, Not Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patients with histological diagnosis of prostate cancer.
- •\- Patients treated with radical therapy (radical prostatectomy or external beam radiotherapy, with or without adjuvant therapy) showing a serum increase in PSA values \= 0\.2 ng / mL.
- •\- Age \= 18 years.
- •\- Able to sign the informed consent for the execution of the examination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 30
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 30
Exclusion Criteria
- •\- Patients \<18 years.
- •\- Medical conditions that may significantly interfere with study compliance.
- •\- Prior or ongoing hormone therapy.
- •\- Contraindications to the PET / MR study (eg pacemaker wearers, etc.)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
Clinical study of prostate cancer dagnositic makers using genetic polymorphismsProstate cancerJPRN-UMIN000019278Kyoto University2,000
Unknown
N/A
Follow-up study for localized prostate cancer treated by hormonal therapy or radical prostatectomy.Prostate cancerJPRN-UMIN000000570J-CaP study group2,000
Completed
Phase 2
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer PatientsProstate CancerNCT00919035Oncology Specialists, S.C.21
Recruiting
N/A
PROstate cancer follow-up care in Secondary and Primary hEalth Care: PROSPEC study.Prostate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.NL-OMON24717Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands390
Completed
Phase 2
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC PatientsProstate CancerNCT00654186Oncology Specialists, S.C.32